This article is more than 5 years old. Information may no longer be current.
Takeda launches pilot program of wearable digital technology for IBD patients
Click Here to Manage Email Alerts
Takeda has partnered with Texas Digestive Disease Consultants and Vanderbilt University Medical Center to launch iBData, a pilot program involving wearable digital watch technology that will enable patients with inflammatory bowel disease to track their symptoms and lifestyle factors, and report them to their health care providers, according to a press release.
“The wearable aspect of the technology being used for iBData provides an opportunity to investigate how we as physicians monitor, assess and treat our patients,” Tim Ritter, MD, medical director of luminal research at Texas Digestive Disease Consultants, said in the press release.
The initial rollout of the program — comprising about 100 patients — will collect data on symptoms, triggers and aggravating factors, and report them to physicians to improve communication between patients and providers, according to the press release. The goal is to facilitate productive and ongoing conversations for improved understanding of each individual patient’s condition, which may ultimately improve outcomes.
“We are very excited about this project and its potential for both patients and physicians,” Dawn M. Beaulieu, MD, assistant professor of medicine in the division of gastroenterology, hepatology and nutrition at Vanderbilt University Medical Center, said in the press release. “Giving patients the power to capture robust, real-time monitoring of their symptoms will help us as physicians to create a personalized treatment plan. Our hope is that this will ultimately result in better disease control and improved IBD care.”
The program “will explore new ways to transform care by generating novel insights into the patient experience that physicians can directly utilize,” Stephanie Brown, vice president, head, Specialty Business Unit, Takeda, said in the press release.
Disclosures: Brown is employed by Takeda. Healio Gastroenterology was unable to confirm Ritter’s and Beaulieu’s relevant financial disclosures.